Bioavailability and pharmacokinetics of inhaled drugs

Inhalation Aerosols: Physical and Biological Basis for Therapy

Volumn , Issue , 2006, Pages 187-218

  Adjei, Akwete L ^a   Gupta, Pramod K ^b   Qiu, Yihong ^c  

^a Kos Pharmaceuticals Inc   (United States)

^b BAUSCH AND LOMB   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123027266     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Sciarra JJ, Cutie A. Aerosols. In: Remington Pharmaceutical Sciences. 17th ed. Mack Publishing, Philadelphia: Lippincott Williams & Wilkins, 1985:1662-1677.
2. Adjei A, Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy human male volunteers. Pharm Res 1990; 7:565-569.
3. Gupta PK, Hickey AJ. Contemporary approaches in aerosolized drug delivery to the lung. J Control Rel 1991; 17:129-148.
4. Forrest JB. Lower airway: structure and function. In: Morén F, Newhouse MT, Dolovich MB, eds. Aerosols in Medicine. Principles, Diagnostics and Therapy. Chapter 2. Amsterdam: Elsevier, 1985.
5. Adjei A, Sundberg D, Miller J, Chun A. Bioavailability of leuprolide acetate following nasal delivery to rats and healthy humans. Pharm Res 1992; 9:244-249.
6. Adjei A, Lee D, Reiland T. Bioavailability of leuprolide following administration of inhalation aerosols to beagle dogs. J Aerosol Med 1991; 4(suppl 1):263.
7. Oberdorster O. Alveolar clearance of inhaled particles and drugs. Presented at Respiratory Drug Delivery III, Keystone, CO, March 26-30, 1990.
8. Ganderton D, Jones TM, eds. Drug Delivery to the Respiratory Tract. Ellis Horwood Series in Biomedicine, 1987:95-114.
9. Martin AR, Kwok DY, Finlay WH. Investigating the evaporation of metered-dose inhaler formulations in humid air: single droplet experiments. J Aerosol Med 2005; 18(2):218-224.
10. Dhand R, Tobin MJ. Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Eur Respir J 1996; 9:585-595.
11. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ. Aerosol delivery from a metered-dose inhaler during mechanical ventilation. Am J Respir Crit Care Med 1996; 154:382-387.
12. Fink JB, Dhand R, Grychowsky J, Fahey PJ, Tobin MJ. Reconciling in vitro and in vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation and defining efficiency-enhancing factors. Am J Respir Crit Care Med 1996; 159:63-68.
13. Adjei A, Carrigan PJ. Pulmonary bioavailability of LH-RH analogs: some biopharmaceutical guidelines. Presented at Respiratory Drug Delivery III. Wifflamsburg, VA, May 16-22,1992.
14. Physician's Desk Reference, 48th ed., 1994.
15. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung. Int J Pharm 1992; 88:63-73.
16. Yamamoto A, Umemori S, Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol 1994; 46:14-18.
17. Li Y, Mitra AK. Effects of formulation variables on the pulmonary delivery of insulin. Drug Dev Ind Pharm 1994; 20:2017-2024.
18. Broadhead J, Edmond Rouan SK, Hau I, Rhodes CT. The effect of process and formulation variables on the properties of spray-dried 0-galactosidase. J Pharm Pharmacol 1994; 46:458-467.
19. Ganderton D, Kassem NM. Dry powder inhalers. In: Ganderton D, Jones T, eds. Advances in Pharmaceutical Sciences. Vol. 6. 1992:165-191.
20. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45:469-473.
21. Gardner LU. Studies on the relation of mineral dusts to tuberculosis: I. The relatively early lesions in experimental pneumoconiosis produced by granite inhalation and their influence on pulmonary tuberculosis. Am Rev Tuberc 1920; 4:734-753.
22. Amdur MD. The effect of aerosols on the response to irritant gases. In: Davies CN, ed. Inhaled Particles and Vapors. London: Pergamon Press, 1961.
23. Goodlow RJ, Leonard FA. Viability and infectivity of microorganisms in experimental airborne infection. Conference on Airborne Infection. Bacter Rev 1961; 25:182-187.
24. Task Group in Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys 1966; 12:173-207.
25. Gonda I. Study of the effects of polydispersity on regional deposition in the respiratory tract. J Pharm Pharmacol 1981; 33:52P.
26. Ferron GA. The size of soluble aerosol particles as a function of the humidity of the air. Application to the human respiratory tract. J Aerosol Sci 1977; 8:251-267.
27. Hiller FC, Mazumdar MK, Wilson JD, Bone RC. Effect of low and high relative humidity on metered dose bronchodilator solution and powder aerosols. J Pharm Sci 1980; 69:334-337.
28. Gonda I, Kayes JB, Groom CV, Fildes FJT. Characterization of hygroscopic inhalation aerosols. In: Stanley-Wood N, Allen T, eds. Particle Size Analysis. New York: J. Wiley & Sons, 1981:31-43.
29. Hickey AJ, Gonda I, Irwin WJ, Fildes FJT. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci 1990; 79:1009-1014.
30. Borgstrom L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990; 7:1068-1070.
31. Adjei A, Gupta P. Pulmonary delivery of therapeutic peptides and proteins. J Control Rel 1994; 29:361-373.
32. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34:311-315.
33. Mitchell EW, Schanker LS, Brown RA. Species comparison of drug absorption from the lung after aerosol inhalation and intratracheal injection. Drug Metab Disp 1986; 14:79.
34. Fazio F, La Fortuna C. Effect of inhaled salbutamol on muociliary clearance in patients with chronic bronchitis. Chest 1981; 80:827-830.
35. Smaldone GC, Messina MS. Flow limitation, cough, and patterns of aerosol deposition. J Appl Physiol 1985; 59:515-520.
36. FOI, New drug application (NDA) 21-868, for Exubera (insulin recombinant deoxyribonucleic acid [rDNA] origin powder for oral inhalation).
37. Kilburn KH. Functional morphology of the distal lung. Int Rev Cytol 1974; 37:153-270.
38. Agnew JE. Physical properties and mechanism of deposition of aerosols. In: Clarke SW, Pavia D, eds. Aerosols and the Lung: Clinical and Experimental Aspects. London: Butterworths, 1984:71-91.
39. Bowden DH. Macrophages, dust, and pulmonary diseases. Environ Lung Res 1987; 12:89-107.
40. Brain DB, Valberg PA, Sneldon S. Mechanisms of aerosol deposition and clearance. In: Morén F, Newhouse MT, Dolovich MB, eds. Aerosols in Medicine. Principles, Diagnostics and Therapy. Chapter 5. Amsterdam: Elsevier, 1985.
41. Weibel ER. Morphometry of the Human Lung. Berlin: Springer-Verlag, 1963:1-151.
42. Bouhuys A. The Physiology of Breathing. New York: Grune & Stratton, 1977:60-232.
43. Williams R. Bioequivalence and therapeutic equivalence. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical Bioequivalence. Chapter 1. New York: Marcel Dekker, 1991.
44. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA, USA: Technomic Publishing, 1993.
45. Veng-Pedersen P. Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (part 1). Clin Pharmacokinet 1989; 17:345-366.
46. Ivan J, Minker E, Vass K, and Lang J. Experimental study on the kinetics of mucocilliary activity in rabbit airways. Acta Physiol Hung 1995; 83(2):105-111.
47. Bois FY, Tozer TN, Hauck WW, Chen M, Patnaik R, Williams R. Bioequivalence: performance of several measures of rate of absorption. Pharm Res 1994; 11:966-974.
48. Veng-Pedersen P. Model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response. 1. Theoretical analysis. J Pharm Sci 1980; 69:298-305.
49. Cutler D. Linear system analysis in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6:265-282.
50. Wagner JG. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J Pharm Sci 1983; 72:838-842.
51. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Res Crit Care Med 2002; 166:1240-1247.
52. Qiu Y, Gupta P, Cheskin H, Adjei L. Pulmonary bioavailability and absorption characteristics of the 5-lipoxygenase inhibitor, Abbott-79175, in beagle dogs. Int J Pharm 1995; 115:95-102.
53. Charnick SB, Yu Z, Athill LV, Karara AH, Tse FLS, Lau DTW. Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral and inhalation dosing in the rat. Biopharm Drug Disp 1994; 15:317-327.
54. Gueriguan JL, Chiu YH, Jordan A, Schaffenburg CA, Sobel S. Regulatory perspective of peptide and protein drug development. In: Lee VH, ed. Peptide and Protein Drug Delivery. Chapter 22. New York: Marcel Dekker, 1991.
55. Forgue ST, Colburn WA. Pharmacodynamic models in bioequivalence. In: Welling PG, Tse FLS, Dighe SV, eds. Pharmaceutical Bioequivalence. Chapter 11. New York: Marcel Dekker, 1991.
56. Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet 1994; 26:1-6.